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1. Abstract 1 
Background. Guidelines for cervical cancer screening have been updated to include human 2 
papillomavirus (HPV) testing, which is more sensitive compared to cytology in detecting 3 
cervical intraepithelial neoplasia. Because of its increased sensitivity, a negative HPV test is 4 
more re-assuring for a woman that she is at low-risk for precancerous cervical lesions than a 5 
negative Pap test. Prompted by the inadequate translation of HPV test-based screening guidelines 6 
into practice, we aimed to synthesize the literature regarding healthcare providers (HCPs) 7 
knowledge, attitudes and practices related to HPV testing and the influence of psychosocial 8 
factors on HCPs acceptability of HPV testing in primary cervical cancer screening. 9 
Methods: We searched Medline, Embase, PsycINFO, CINAHL, Global Health, and Web of 10 
Science for journal articles from January 1, 1980 to July 25, 2018. A narrative synthesis of HCPs 11 
knowledge, attitudes and practices related to HPV testing is provided. Informed by the Patient 12 
Pathway framework, we used deductive thematic analysis to synthesize the influence of 13 
psychosocial factors on HCPs acceptability of HPV testing. 14 
Results: The most important HCPs knowledge gaps are related to the superior sensitivity of the 15 
HPV test and age specific guidelines recommendations for HPV testing. 30-50% of HCPs are not 16 
compliant with guideline recommendations for HPV testing e.g., screening at shorter intervals 17 
than recommended. Barriers, facilitators and contradictory evidence of HCPs’ acceptability of 18 
the HPV test are grouped by category: a) factors related to the HCP; b) patient intrinsic factors; 19 
c) factors corresponding to HCP’s practice environment; d) healthcare system factors. 20 
Conclusions: HCP’s adherence to guidelines for HPV testing in cervical cancer screening is 21 
suboptimal and could be improved by specialty organizations ensuring consistency across 22 





identified in this review may facilitate the translation of HPV testing recommendations into 24 
practice.      25 
Keywords: HPV test; cervical cancer screening; healthcare providers; knowledge, attitudes and 26 
beliefs; HPV test acceptability; cervical cancer screening guidelines 27 
 28 
2. Introduction  29 
Worldwide, approximately 530,000 women are newly diagnosed with cervical cancer 30 
annually, and almost 266,000 will die from the disease(1). As long-term persistent infection with 31 
an oncogenic genotype of human papillomavirus (HPV) has been found to be a necessary risk 32 
factor for developing cervical cancer(2, 3), recommendations for cervical screening to include the 33 
HPV DNA test together with cytology (co-testing) were issued in the US as early as 2002(4). In 34 
recent years, evidence has accumulated that in the primary cervical cancer screening setting, 35 
HPV testing has superior sensitivity compared to cytology in detecting cervical intraepithelial 36 
neoplasia(5-8) and that screening intervals can be extended to five years or beyond–compared to 37 
three years for cytology alone–in women with a negative HPV test(9-11). Consequently, in the last 38 
decade, recommendations of major health organizations in the US, Europe, and Australia have 39 
been updated repeatedly and currently include HPV testing–either as a stand-alone test or as co-40 
testing–for primary cervical cancer screening of women older than 30 years (or even as low as 25 41 
years in some jurisdictions)(12-15). 42 
In the context of continuous change in primary cervical cancer screening recommendations 43 
(for both cytology and HPV testing) related to women’s age of screening initiation, age-specific 44 
screening intervals and screening discontinuation, research indicates that less than 20% of 45 
healthcare providers (HCPs i.e., family practitioners (FPs), internal medicine specialists (IMs), 46 





US follow all age-related guideline recommendations released in 2009 or in 2012 by the 48 
American College of Obstetricians and Gynecologists (ACOG),  American Cancer Society 49 
(ACS), and the United States Preventive Services Task Force (USPSTF)(16, 17). Poor practice 50 
implementation of HPV testing guidelines have been driven by HCPs’ worry that increasing 51 
screening intervals with the HPV test would put women at increased risk of pre-cancer and 52 
cancer(18) and perception that the HPV test alone is less effective than cytology (Pap) in detecting 53 
pre-cancerous lesions(19). HCPs are concerned that gynecologic health issues other than cervical 54 
cancer prevention could be missed if yearly examinations are not performed. Women might feel 55 
less motivated to consult a doctor annually if the cervical cancer screening interval is increased 56 
to 3 years or more by using HPV test-based screening instead of annual Pap screening(17, 20).  57 
To our knowledge, there has been no review of psychosocial factors that influence HCPs’ 58 
recommendations of the HPV test in primary screening for cervical cancer to date. This study 59 
synthesizes the literature regarding current HCPs practices and attitudes related to HPV testing 60 
and the influences of psychosocial factors on HCPs acceptability of HPV testing in primary 61 
cervical cancer screening. It is important to more comprehensively understand HCPs’ concerns 62 
related to modified cervical cancer screening recommendations in order for interventions to 63 
adequately address these concerns and more effectively translate the latest guideline 64 
recommendations for HPV testing into practice to ensure optimal cervical cancer screening. 65 
3. Materials and Methods  66 
The review was guided by the following three research questions: 1) “What are HCPs’ 67 
perceptions related to HPV testing in primary screening for cervical cancer?”, 2) “How is HPV 68 
testing used by HCPs in primary screening for cervical cancer?”, and 3) “How do psychosocial 69 





We searched Medline, Embase, PsycINFO, CINAHL, Global Health, and Web of Science for 71 
journal articles between January 1, 1980 and July 25, 2018. The search strategy was developed 72 
for Medline by our research team and adapted for the other databases1. The following eligibility 73 
criteria were applied: 1) Population: HCPs involved in primary screening2  for cervical cancer; 74 
2) Outcome: knowledge, attitudes, beliefs, and acceptability3 related to using HPV testing in 75 
primary cervical cancer screening; 3) Study design: empirical studies, without restrictions of 76 
study methodology; and 4) Languages: English, French, or German. References retrieved from 77 
database searches were saved in EndNote and duplicates were removed. We used a combination 78 
of keywords in EndNote to identify references related to healthcare providers and HPV test use 79 
(Figure 1). Then, we selected references in two phases: in phase one, we screened for eligible 80 
articles based on titles and abstracts, and in phase two, full text articles were retrieved and read, 81 
and the final set of eligible articles was identified. In phase two, the selection of references was 82 
performed independently by two researchers (KW and OT) and disagreements on whether an 83 
article should be retained were mediated by the senior researcher (ZR). In the second phase, we 84 
decided to exclude articles referring to HCPs not directly involved in the clinical decision of 85 
using the HPV test in primary screening (e.g., HCPs working in laboratories, students, etc). 86 
Qualitative (e.g., quotes) and quantitative (e.g., proportions, odds ratios) data from 87 
included studies were extracted and organized in an Excel spreadsheet in the following 88 
categories and were used in the data synthesis phase: knowledge, attitudes/beliefs, practice and 89 
factors related to HPV test acceptability. In line with the first two research questions, we provide 90 
                                                 
1 The search strategy for Medline is available at: 
https://www.crd.york.ac.uk/PROSPEROFILES/78254_STRATEGY_20181017.pdf 
2 In primary screening, the HPV test (including HPV co-testing) is used in women with no history of cervical 
cytological abnormalities i.e., abnormal Pap results. The addition of the HPV DNA test to cytology (Pap test) is 
known as co-testing. 
3 The term acceptability defined herein includes HPV test uptake (already recommended by the HCPs); and 





a narrative synthesis of HCPs’ knowledge, attitudes and beliefs related to the HPV test and its 91 
uptake and intentions to be used in primary screening for cervical cancer. For the third research 92 
question, we used the Patient Pathway framework(21)– a conceptual model that categorizes 93 
factors with influence on the patient-HCP encounter and the level of preventive care that a 94 
patient receives–to synthesize the influence of psychosocial factors on HPV test acceptability. 95 
The Patient Pathway framework has been previously used in explaining screening 96 
mammography referral rates(22) and stipulates that the probability that a patient will receive 97 
screening services by clinicians is determined by factors related to the HCP, patient intrinsic 98 
factors, and characteristics specific to patients’ and HCP’s environment(21). In our synthesis, we 99 
conceptualized environmental factors as two different entities: factors corresponding to HCP’s 100 
practice environment and healthcare system factors. Informed by the Patient Pathway framework 101 
we performed deductive qualitative thematic analysis and grouped psychosocial factors into four 102 
categories: a) factors related to the HCP, b) patient intrinsic factors (from the perspective of 103 
HCPs), c) factors corresponding to HCP’s practice environment and d) healthcare system factors. 104 
For each category, we synthesized evidence of factors’ influence on HPV test acceptability into 105 
barriers, facilitators, and contradictory evidence (i.e., evidence for both barriers and facilitators), 106 
and presented the results in tabular form. Deductive analysis was performed by OT and 107 
supervised by ZR. 108 
4. Results 109 
In Figure 1 we present the study selection diagram. In total, we retained 32 studies, four used 110 
qualitative(23-26) and 28 used quantitative methodology(2, 16-20, 27-47). Included studies covered 111 
HCPs opinions from five continents: Europe (i.e., UK(47), Germany(38) and Italy(39)), North 112 





and Nigeria(25)), Asia (i.e., China(27), Jordan(45),South Korea(33) and Thailand(37)) and Oceania 114 
(i.e., Australia(32)). Details of each included study can be found in Appendix A. 115 
 116 
4.1 Knowledge  117 
While HCPs were found to have up-to-date knowledge related to the prevalence of HPV 118 
infection and the causal relationship between persistent infection with high-risk HPV and 119 
cervical cancer, gaps in knowledge were identified as fewer than 50% of HCPs in Hong Kong 120 
knew that infection can occur in the absence of identifiable sexual risk factors and that HPV 121 
genotypes associated with cervical cancer differ from those associated with genital warts(27). As 122 
expected, HCPs’ knowledge about HPV and HPV testing increased over time after 2006 when 123 
the first HPV vaccine was approved which represented a turning point in cervical cancer 124 
prevention. While in 2006, 10% of US physicians were not even aware that an HPV test was 125 
already available(36), data from 2011 showed that 47% of physicians and nurses in Cameroon 126 
knew that the HPV test can be used for cervical cancer screening(28). In the UK, Patel et al (2016) 127 
found increased HPV test knowledge among nurses (>70% correct answers) who participated in 128 
regular screening education sessions; their knowledge gaps were related to the sample collection 129 
procedure for HPV testing and reassurance offered by a negative HPV test result for low-risk of 130 
cervical lesions (47).  131 
Surprisingly, despite recommendations of specialty organizations in the US, Europe and 132 
Australia to include HPV testing in primary screening for cervical cancer(12-15), HPV test 133 
knowledge among HCPs remains insufficient, highlighting a lack of understanding of the 134 





in Hong Kong (in 2010) and Italy (in 2015) were unaware that HPV testing (including co-136 
testing) is more sensitive than cytology in detecting high-grade cervical intraepithelial 137 
neoplasias(27, 48), that the HPV test is not generally recommended in primary screening of women 138 
younger than 30(27, 48), that a negative HPV test (without cytology), in Italy, allows extension of 139 
the cervical cancer screening interval to five years(48), and that no recommendations have been 140 
issued for more frequent HPV testing for cervical cancer in women diagnosed with genital 141 
warts(27). In the US, Teoh et al. (2015) found that only 5.7% of HCPs were knowledgeable about 142 
all age specific cervical cancer guidelines updated in 2012 by the ACS, ASCCP and ASCP4 but 143 
83.7% of respondents knew that in women 30-65 years the recommended screening interval for 144 
co-testing (combined Pap and HPV test) increased from 3 to 5 years(40).  145 
Among OB/GYNs in Italy, correlates of higher HPV test knowledge in primary screening for 146 
cervical cancer were found to be related to: HCPs perceiving their cervical cancer screening 147 
knowledge to be good to excellent (OR = 1.46; CI: 1.12–1.91), higher number of hours worked 148 
(OR = 1.02; CI: 1.01–1.03), and knowledge that the Pap test is not recommended annually(48). 149 
4.2 Attitudes and beliefs  150 
HCP’s attitudes and beliefs were grouped into five sub-categories: acceptability of guidelines, 151 
beliefs about test efficacy, communication of results to patients, HPV self-sampling and point of 152 
care testing, and beliefs about screening intervals. 153 
4.2.1 Acceptability of guidelines 154 
Irwin et al. (2006) and Boone et al. (2014) found that half of US HCPs in their study 155 
considered cervical cancer screening guidelines valuable(16, 36) while 35% of all HCPs do not 156 
                                                 
4 ACS: American Cancer Society; ASCCP: American Society for Colposcopy and Cervical Pathology; ASCP: 







consider current guidelines clinically reliable and appropriate (including 59% of obstetrics-157 
gynecologists (OB/GYNs), 28% of family practitioners (FPs), 38% of nurse practitioners (NPs) 158 
and physician assistants (PAs), and 26% of internal medicine specialists (IMs))(16). While over 159 
90% of OB/GYNs in Italy(48) and  over 80% of colposcopists in Canada(35) were comfortable 160 
with recommendations endorsing HPV testing in primary screening for cervical cancer and 161 
believed that guidelines released by scientific associations and national and international 162 
agencies are very useful in cervical cancer prevention, 41% of OB/GYNs in Italy suggested that 163 
cervical cancer screening should be done annually (against recommendations), irrespective of the 164 
test used(48). 165 
4.2.2 Beliefs about test efficacy 166 
Approximately 85% of HCPs in the US perceived liquid-based cytology as the most effective 167 
test for reducing cervical cancer mortality, followed by co-testing (64-82%) and Pap (~50%)(29, 168 
30, 34, 43). Despite the fact that over 70% of HCPs (OB/GYNs, IMs and FPs) in the US agree that 169 
the HPV test alone represents an effective screening modality(19), it was generally perceived to be 170 
less effective than Pap(19, 38), co-testing(19), or colposcopy(38). Among Italian OB/GYNs, Caglioti 171 
et al. (2017) found that the preferred cervical cancer screening test in women ≥30 years was Pap 172 
(~39%) (followed by an HPV test in case of an abnormal Pap test); about 28% of OB/GYNs 173 
preferred the HPV test (with triage using the Pap test in case of a positive HPV-DNA test) or co-174 
testing(48). In contradiction with recommendations for cervical cancer screening, ~41% of 175 
OB/GYNs preferred the HPV test alone to screen women aged <30 years(48). In less developed 176 
healthcare systems, OB/GYNs believe that introducing HPV testing into antenatal care would be 177 
an innovation due to its increased sensitivity in detecting precancerous lesions and could 178 





easy to implement and useful in planning next steps after an abnormal Pap result and in 180 
estimating the cancer risk(41).  181 
4.2.3 Communication of results to patients 182 
Lin et al. (2015) found that 75% of HCPs ordering a co-test, would engage in discussing 183 
possible results with their patients; compared to Pap positive and HPV test positive (co-test) 184 
results, HCPs were more likely to believe that Pap negative and HPV positive co-test results 185 
would be too complicated for patients to understand and could trigger patients’ worries related to 186 
treatment options(42). HCPs believe that providing positive HPV test results require appropriate 187 
communication strategies to alleviate women’s stigma associated with an sexually transmitted 188 
infection (STI) diagnosis(26). 189 
4.2.4 HPV self-sampling and point of care testing 190 
HPV testing on self-collected cervical samples (i.e., self-sampling) represents an alternative to 191 
physician collected samples and is performed by using a specially designed self-sampling 192 
devices which are commercially available in many countries. Interviews with HCPs revealed that 193 
discussing the self-collection option with under-screened women is probably more important 194 
than offering them alternative diagnostic procedures (i.e., cytology versus HPV testing)(26). 195 
Trope et al (2009) found high perceived benefits and increased preference among field-oriented 196 
HCPs (compared to hospital-oriented) for a new hypothetical protocol that includes HPV self-197 
sampling at home for women living in villages, followed by visual inspection with acetic acid 198 
(VIA) in HPV positive women; this protocol would represent an alternative to performing VIA 199 
in all women(37). In the US Affiliated Pacific Islands, more than 30% of HCPs felt that a point-200 





allowing for therapeutic measures to be taken on the same day) would be better than the 202 
conventional HPV test(34). 203 
4.2.5 Beliefs about screening intervals 204 
Encouragingly, Regier et al. (2013) found a significant increase over time in the proportion of 205 
colposcopists who openly advocate for HPV testing as the primary tool in cervical cancer 206 
screening (19% increase from 2010 to 2011, CI: 0.01–0.38); colposcopists’ confidence that their 207 
personal attitudes would affect family practitioners’ attitudes toward primary HPV testing 208 
increased by 13% from 2010 to 2011 (CI: 0.01–0.30)(35). Most HCPs showed positive attitudes 209 
towards extending the screening interval in women ≥30 years with normal co-test results; 210 
providers who recommended a three year interval after a normal co-test, reported more often that 211 
extending routine screening to three years would be good (80%), easy (67%) and beneficial 212 
(68%) compared to providers who recommended annual screening after a normal co-test (p < 213 
.05)(18). Roland et al. (2013) found that after normal co-test results, ~24% of HCPs perceived 214 
extending the screening interval in women ≥30 years as being harmful, difficult or bad(20). In 215 
2010 and 2011, 40% and 53% of colposcopists, respectively, felt that four years between HPV 216 
tests was too long(35). Benard et al. (2016) found that educational interventions (grand rounds, 217 
academic detailing sessions, etc.) significantly increased the odds of HCPs reporting that 218 
extending the screening interval for women with a normal co-test result to three years would be 219 
good (OR 6.45, p = 0.038), easy (OR = 5.18, p = 0.032), beneficial (OR = 8.53, p = 0.034), and 220 






4.3 Practice and intentions 223 
In Table 1, we present a synopsis of the applicable cervical screening recommendations used 224 
by each author in relation to the year of data collection as shown in the far right-hand column. 225 
Against recommendations for age-specific practices, 31-43% of HCPs would prematurely initiate 226 
cervical screening before age 21 with either cytology or co-testing(16, 17). For women in the age 227 
range 21-29, practitioners generally over-screened by performing annual Pap tests (74% of 228 
OB/GYNs)(17), 35-85% of HCPs (lowest proportion among OB/GYNs) inappropriately screened 229 
with the co-test(36, 40, 44, 46) and recommended it yearly or every three years (13-42% of 230 
OB/GYNs, FPs, IMs, NPs, PAs)(16, 44). Cooper et al. (2017) found that for women less than 25 231 
years old, approximately 24% of OB/GYNs and 43-61% of FPs and IMs would incorrectly 232 
recommend the HPV test alone(46). In women aged 30-65 years, reported co-testing use is highly 233 
variable: 28-80% among HCPs in the US (17, 19, 20, 30, 36, 40) and 28% among OB/GYNs in Italy(39). 234 
In the US, 23-43% of HCPs stated they do not conduct an HPV test at all in women 30-65 years 235 
old(17, 30). In women aged 30 to 65 years, with a normal Pap result and negative HPV test results, 236 
over-screening remained an issue as 25-48% of HCPs (higher among OB/GYN than FP) 237 
perform/would perform co-testing every three years instead of the recommended five years(16, 40, 238 
46, 48) or even at one or two year intervals (20-55% of physicians)(19, 30, 41, 46, 48). After a negative 239 
HPV test, 44% of Italian OB/GYNs comply with European guidelines and recommend the next 240 
HPV test after five years(48). In women ≥30 years old, most OB/GYNs (78-84%), and to a lesser 241 
extent IMs and FPs (45-64%) prefer to use the Pap test in primary screening, with triage using 242 
HPV testing in case of a positive Pap(30, 48). Remarkably, Perkins et al. (2013) found that 53% of 243 





providers continue to recommend ongoing screening(16, 17, 40) and ~11% continue to use co-245 
testing(16, 40). 246 
HCPs reported low to medium intentions (34-60%) to change their screening practices from 247 
annual cytology to extended three or five yearly co-testing in women aged >25 years(32, 33) or > 248 
30 years old women(43), if new recommendations were about to be released. Intentions of HCPs 249 
to recommend HPV self-sampling varied between 32-78%, if the test were proven to have high 250 
sensitivity, specificity, cost-effectiveness and were acceptable by the patient(31, 34). 251 
 4.4 Influence of psychosocial factors on HCPs acceptability of HPV testing 252 
In Table 2 we present (informed by the Patient Pathway framework) the influence of factors 253 
on HPV test acceptability grouped into: 1) factors related to the HCP, 2) patient intrinsic factors, 254 
3) factors corresponding to HCP’s practice environment and 4) healthcare system factors. 255 
5. Discussion 256 
In the present review, we included published articles of qualitative and quantitative 257 
methodology to provide the most comprehensive synthesis of psychosocial factors (i.e., 258 
knowledge, attitudes and behaviors) associated with HCPs acceptability of HPV testing in 259 
primary cervical cancer screening. 260 
Surprisingly, we found that 30-50% of HCPs did not follow age-specific guideline 261 
recommendations for HPV testing and that over-screening (e.g., screening at shorter intervals 262 
than recommended by guidelines) with the HPV test and/or cytology represents a widespread 263 
practice. In the context of HPV-based testing, over-screening (e.g., beginning of screening before 264 
25 years, yearly testing in women aged 30-65) could inflict psychological distress on women 265 
receiving a positive HPV test result, has no clinical relevance since most HPV infections are 266 





knowledge of cervical cancer screening guidelines(40) and HPV test knowledge gaps (e.g., higher 268 
sensitivity of the HPV test compared to cytology (Pap) in detecting high-grade cervical 269 
intraepithelial neoplasia and/or a negative HPV test allowing the extension of screening intervals 270 
to 5 years or beyond)(27, 39) could explain low HCPs’ compliance with guidelines. While 271 
educational interventions were found to positively influence HCPs attitudes towards HPV test-272 
based cancer screening guidelines (i.e., considering extending the screening interval after a 273 
normal co-test as being good, easy and beneficial)(41), these changing attitudes might not 274 
translate into implementation of guidelines. For example, Caglioti et al. (2017) found that ~40% 275 
of HCPs who viewed screening guidelines as useful still considered that screening should be 276 
done annually, independent of the test used(39). On the other end of the spectrum are HCPs who 277 
consider current guidelines clinically unreliable and inappropriate (~ 35% of HCPs)(16) and who 278 
might be reluctant to change their practice; this could be the case, especially if screening 279 
guidelines in their jurisdiction/health system/organization do not incorporate HPV testing(26, 36, 280 
40), their administration and/or colleagues discourage the use of HPV test-based screening(2, 20, 36) 281 
or they feel at risk for liability when adopting extended screening intervals and cervical dysplasia 282 
is missed(20). 283 
The inconsistent translation of HPV test-based screening guidelines into practice may likely 284 
be complicated by the multiple changes in recommendations (guidelines) since 2001 by different 285 
national and international specialty organizations that were often out of synch related to the 286 
optimal age of screening debut, age specific screening intervals and discontinuation of screening 287 
(see Table 1). For example, the contradictory influence of HCPs specialty on HPV test 288 
acceptability could be explained by the discrepancies in HPV test recommendations by different 289 





professional organization or those issued by other national or international authorities (which 291 
may be slightly different). An important barrier towards adopting extended screening intervals 292 
with the HPV test (i.e., not sooner than every 3 years) is represented by the long-standing annual 293 
Pap screening practice, which is no longer recommended by any organization. For women, the 294 
annual Pap screening could represent a culturally-embedded and difficult to dismantle 295 
expectation while for physicians it could be associated with economic incentives for continuing 296 
annual gynecologic follow-ups. This conclusion is further explained in that HCPs (notably, 297 
OB/GYNs) are worried that longer screening intervals would put patients at increased risk for 298 
cancer (with potential risk of HCP liability), would then result in higher rates of pre-cancer(18) 299 
and/or would negatively influence adherence to other annual examinations (e.g., pelvic 300 
examination) or screening tests(17, 20).  301 
Among high-income countries, HPV testing is being increasingly incorporated into cervical 302 
screening programs. Organized, HPV test-based screening programs (that replace cytology) are 303 
in various stages of implementation in Australia(15, 49), the Netherlands(49, 50), Sweden(49) and 304 
Italy(49) while the United Kingdom(51) and Norway(49) will begin in 2019 and New Zealand(52) 305 
will follow in 2021. The overview of barriers and facilitators provided in our synthesis is 306 
especially useful for understanding HPV test acceptability in opportunistic cervical cancer 307 
screening environments where adherence to the latest screening recommendations is highly 308 
dependent on HCPs opinions–as opposed to organized programs where screening follows a pre-309 
determined strategy–and could assist policy makers in planning and implementation of HPV test-310 
based cervical cancer screening programs in new jurisdictions. Given the successful results of 311 
national HPV vaccination programs, it is highly likely that national HPV screening programs 312 





Another major innovation with potential to increase acceptability and lower cost is HPV 314 
testing on self-collected cervical samples (self-sampling). Self-sampling “represents a new 315 
advance in cancer control that is unequivocally empowering to women”(53) as it can effectively 316 
reach, in both organized and opportunistic cervical cancer screening environments, under-317 
screened (and often marginalised) women in which about half of all invasive cervical cancers are 318 
diagnosed(53). Despite  a slightly lower sensitivity and specificity in detecting cervical 319 
intraepithelial neoplasia (CIN2 and CIN3) of HPV testing on self-samples than of HPV testing 320 
on a clinician-taken sample(54, 55), Nelson et al. (2017) found that 97% of women found self-321 
sampling to be generally acceptable, 65% would prefer self-sampling over clinician-based 322 
sampling for HPV testing and considered self-sampling less embarrassing, respecting privacy 323 
and easy to use(56). In our review, we found that HCPs viewed self-sampling as a facilitator of 324 
HPV testing as it alleviates women’s concerns about privacy and body discomfort during Pap 325 
examination, has the potential to reach women in underserved locations and reduces the burden 326 
of women’s return to the medical system(23, 24). Strategies to increase HCPs recommendations for 327 
self-sampling should take into consideration HCPs worries that self-sampling could be 328 
associated with missed opportunities to address other health issues and that women’s decreased 329 
health literacy represents a barrier to an efficient screening, mostly due to poor quality of the 330 
self-collected sample (23, 31). 331 
We found the Patient Pathway Framework useful to synthesize factors that influence HCPs 332 
acceptability of the HPV test into following categories: a) HCP specific, b) patient-specific, c) 333 
HCP practice specific and d) healthcare system specific. Importantly, we found an overlap 334 
between patient-specific psychosocial factors related to HPV test acceptability and the results of 335 





primary screening for cervical cancer(57). These overlapping patient-specific factors merit special 337 
consideration as they can act as barriers in the uptake of HPV testing and include: women’s 338 
negative attitudes toward increasing the screening interval, negative emotions and perceptions 339 
related to HPV testing (e.g., shame and anxiety linked to testing for a sexually transmitted 340 
infection), women’s low health literacy (i.e., decreased HPV test knowledge and insufficient use 341 
of health information channels), risky health behaviors (e.g., smoking), low socioeconomic status 342 
and non-white ethnicity(57). Given these additional barriers, it becomes exceedingly important to 343 
recognize that while guidelines, policy changes and training for HCPs to assure improved HPV 344 
screening implementation, we must also make equally strong interventions in gauging, guiding 345 
and educating all women successfully in kind and in synchrony. Failure to engage, consult and 346 
inform women’s needs in the immense task of  347 
changing 70 years of cervical screening practices can lead to confusion and resistance, as has 348 
occurred recently in Australia. Systematic and informed policy decisions must be made with all 349 
stakeholders involved. 350 
Our study has a number of limitations. The synthesis of HCPs’ practice and intentions to use 351 
the HPV test is based mostly on studies conducted in the US (13 out of 16) and cannot be 352 
reliably generalised to HCPs recommendation habits in other countries. The heterogeneity in 353 
healthcare settings, women’s accessibility and affordability of HPV testing and constantly 354 
evolving guidelines for cervical screening further limit the generalizability of our results. Most 355 
studies included in our review originated in North America (22 out of 32) and no data were 356 
included from HCPs who practice in healthcare systems where an organized HPV test-based 357 
cervical screening program exists; this affects the generalisability of our results while prompting 358 





not perform a structured quality appraisal of included studies which could have introduced bias 360 
in the interpretation of barriers and facilitators of HPV test acceptability. 361 
6. Conclusions 362 
While major specialty organizations have included HPV testing in their recommendations for 363 
primary cervical cancer screening, the adherence of HCPs to the guidelines is suboptimal. 364 
Possible explanations include insufficient HPV test and guidelines knowledge as well as the 365 
heterogeneity of published guidelines related to HPV testing recommendations. Psychosocial 366 
barriers of HPV test acceptability can be categorized into: factors related to the HCP (e.g., 367 
concerns related to delaying screening initiation to 25 years, extending testing intervals beyond 5 368 
years), patient intrinsic factors (e.g., stigma and anxiety related to testing for a sexually 369 
transmitted disease), factors corresponding to HCP’s practice environment (e.g., HPV testing 370 
guidelines not endorsed by their healthcare organization) and healthcare system factors (e.g., 371 
opportunistic cervical cancer screening environment). Future research is needed to estimate the 372 
association between psychosocial factors and HPV test acceptability in primary screening for 373 
cervical cancer from the perspective of HCPs practicing in healthcare systems where organized 374 
HPV test-based screening has been implemented. 375 
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1Key word search terms: physician* (any field) OR doctor* (any field) OR provider*(any field) OR HPV test*(any field) 
2Phase 1 exclusion criteria for titles and abstracts: 1) not population of interest (i.e. healthcare providers involved in primary 
screening), 2) not outcomes of interest (psychosocial factors, intentions, correlates of acceptability), 3) not empirical studies, 
4) no abstract 5) not HPV testing in primary screening for cervical cancer, 6) Only knowledge of risk factors for cervical 
cancer, 7) Only HPV knowledge, 8) only Pap related, 9) Only HPV vaccine related 
3Phase 2 exclusion criteria for full text articles: Phase 1 exclusion criteria AND full text not in English, French or German 
AND study population comprise only HCPs not involved in making decisions related to HPV test use (e.g., laboratory 



























Additional records identified through 
other sources (n = 2) 
Articles identified through database 
searching (n = 14 970) 
Screened by combination of keywords 
(n = 8837) 
Duplicates removed (n = 6135) 
Full text articles assessed for eligibility  
(n = 65)  
Articles excluded based on phase 
1 exclusion criteria2 (n = 2112) 
Total number of studies retained 
(n = 32) 
Full text articles excluded based 
on phase 2 exclusion criteria3  
(n = 33) 
Articles screened by title and abstract 
(n = 2177) 
Articles excluded based on key 
word search1 (n = 6660) 
Total number of records 
 (n = 14972) 
 
 
Table 1. Cervical cancer screening recommendations for included quantitative studies over time 
Note: ACS: American Cancer Society; ACOG: American College of Obstetricians and Gynecologists; ASCCP: American Society for Colposcopy and Cervical Pathology; ASCP: 
American Society for Clinical Pathology; EGQACCS: European guidelines for quality assurance in cervical cancer screening(14, 49); KSOG: Korean Society of Obstetrics and 
Gynecology; KMHW: Korean Ministry of Health and Welfare; RANZCOG: The Royal Australian and New Zealand College of Obstetricians and Gynaecologists(50); SGO: 
Society of Gynecologic Oncology; USPTF: United States Preventive Services Task Force; * Interim Guidance Report issued by SGO and ASCCP(12); ** Adequate prior 
screening can be defined as three consecutive negative cytology results or two consecutive negative co-test results within the previous 10 years, with the most recent test performed 
within the past 5 years(51); ¶ data collected before 2012 guidelines change; § For screening practice only the 2012 data was used; ACS, ACOG and USPTF guidelines were issue 
















year of data 
collection 
2001-2003 
Cytology within 3 years 
of sexual activity or at 
age 21 (ACS, ACOG) 
OR at sexual activity 
debut or 20y/KSOG 
Annual (conventional 
cytology) or every 2 years 
(liquid cytology) (ACS, 
ACOG) 
OR annual cytology (KSOG) 
30-70y, in women who have had 3 
consecutive negative cytology results the 
recommended screening interval with 
cytology was 2 to 3 years (ACS, ACOG) 
OR HPV co-testing no sooner than every 3 
years (ACS-preliminary recommendation) ¥ 
OR annual cytology (KSOG) OR biannual 
cytology (KMHW) 










21y, with cytology only 
(ACOG, USPTF, ACS) 
Cytology only, every 2 years 
(ACOG, USPTF, ACS) 
30-65y, cytology every 3 years OR co-testing 
every 3 years (ACOG, USPTF, ACS) 
>70y, in women with 
adequate prior screening 
(ACOG, USPTF, ACS) 
Perkins (2011) 







21y with cytology only 
(ACOG, ACS, USPTF, 
ASCCP, ASCP) 
OR 18 years/ 
(RANZCOG) 
Cytology only, every 3 years 
(ACOG, ACS, USPTF, 
ASCCP, ASCP) 
OR cytology every 2 years/ 
(RANZCOG) 
30-65y, cytology every 3 years OR co-testing 
every 5 years (ACOG, ACS, USPTF, 
ASCCP, ASCP) 
OR cytology every 2 years (RANZCOG) 
>65y, in women with 
adequate prior 
screening** (ACOG, 
ACS, USPTF, ASCCP, 
ASCP) 
OR >69y, (RANZCOG) 
Boone (2014) 
Teoh (2013) 





21y with cytology only 




Cytology every 3 years 
(ACOG, ACS, USPTF, 
ASCCP, ASCP)  
OR cytology every 3-5 years/ 
(EGQACCS-2008) 
OR HPV test alone every 3 
years for women >25y (SGO, 
ASCCP*, ACOG) 
30-65y, cytology every 3 years OR co-testing 
every 5 years (ACOG, ACS, USPTF, 
ASCCP, ASCP) 
OR cytology every 3-5 years (EGQACCS 
2008)  
OR HPV test alone no sooner than every 3 
years (SGO, ASCCP*, ACOG) 
OR HPV testing alone (not co-testing), no 
sooner than every 5 years (EGQACCS-2015) 
>65y, in women with 
adequate prior 
screening** (ACOG, 
ACS, USPTF, ASCCP, 
ASCP)  
OR >60-65y, in women 







Table 2. Barriers and Facilitators of Healthcare Providers Acceptability of the HPV Test in Primary Screening for Cervical Cancer 
Factors related to the HCP 
Barriers Facilitators Contradictory evidence 
• Concern that cervical cancer could be missed if 
screening initiation with the HPV test is delayed 
to 25 y(32) 
• Belief that women > 30 y would fear that cervical 
cancer could be missed by extending the co-test 
screening interval from 1 to 3 years(20) 
• Concern that increasing screening intervals 
beyond 1 year with the co-test would put women 
at increased risk of pre-cancer and cancer(18) 
• Belief that annual exams and other screening tests 
could be missed if Pap is not offered and the 
screening interval after a normal co-test is 
increased to 3 years(17, 20)  
• Belief that using self-sampling could be 
associated with missed opportunities to address 
other health issues(31) 
• Beliefs that delaying screening debut to 25y and 
increasing screening intervals are strategies to 
reduce government costs(32) 
• Belief that discussing the association between a 
STI and cervical cancer could have negative 
emotional effect on women and would be time 
consuming(36) 
• Insufficient knowledge of cervical cancer 
screening guidelines(40)  
• Age > 40 and > 10 years of practice concerned 
about women’s ability to use self-sampling(31) 
• Higher HPV and HPV test knowledge (e.g., 
higher sensitivity of the HPV test in detecting 
precancerous lesions)(36, 39) 
• Less perceived need of information on cervical 
cancer screening(39) 
• Knowledge that the Pap test is not 
recommended annually(39) 
• Educational interventions increase acceptability 
of an interval of 3 years for co-testing(41) 
• Increased cervical cancer knowledge (e.g., 
cervical changes in young women are usually 
low grade and have a high rate of regression) 
was associated with higher acceptability to start 
screening at 25y(32) 
• Respecting guidelines for extended interval 
screening for the Pap test (i.e., 3 years instead of 
annually)(30) 
• Perception that extending the screening interval 
for co-testing is promoted by professional 
journals, professional specialty organizations 
and national health organizations(18) 
• Use of self-sampling method(24) 
• Higher acceptability of co-testing at 3 years 
interval (instead of yearly) in HCPs who 
consider yearly pelvic examination less 
useful(30) 
• Higher acceptability among Asian and Hispanic 
individuals(46) 
 
• Consider screening guidelines 
valuable/HCPs are influenced by 
guidelines(32, 36, 46) 
• Influence from patients (i.e., patients either 
reject extended screening intervals or want 
to know their HPV infection status)(20, 36, 40, 
46) 
• Influence from administration and 
colleagues who discourage use of co-testing 
and extending screening intervals to 3 
years(20) 
• Concerns that integration of HPV testing in 
antenatal care could be associated with 
pregnancy loss(25) 
• Specialty: higher HPV test acceptability in 
OB/GYN than FP(2, 19, 36) or IM(19, 36, 44) or 
opposite effect(32, 46). Compared to IM, 
acceptability in FP was higher(44) or lower(46) 
• Volume of cytology examinations: higher 
Pap volume increase HPV test 
acceptability(30). Increased volume of liquid 
cytology increase(36) or decrease HPV test 
acceptability(30). ≥ 45 screenings/month 
associated with lower HPV test 
acceptability for women ≥30y(46) 
• Gender: Lower acceptability in male HCP(2, 







Table 2 (continued). Barriers and Facilitators of Healthcare Providers Acceptability of the HPV Test in Primary Screening for Cervical Cancer  
Patient intrinsic factors 
Barriers Facilitators Contradictory evidence 
• Women’s low acceptability of the HPV test and/or 
self-sampling(31, 39) 
• Stigma associated with testing for a STI, worry 
about increased cervical cancer screening interval, 
increase perception of cancer risk, fear of 
procedure(23, 35) 
• Irregular Pap testing history and smoking are 
barriers for extending screening intervals in 
women ≥ 30y(20) 
• Decreased health literacy is a barrier for using 
self-sampling(23, 31) 
• High risk for cervical cancer (e.g., history of 
cytological abnormalities, immunocompromised) 
act as barrier to delaying screening debut to 25 y 
and increasing screening intervals in women 
≥30y(20, 32) 
• Increased number of lifetime sexual partners, 
history of STI and sexual abuse act as barrier to 
delaying screening debut to 25 y and increasing 
screening intervals in women ≥30y(20, 32) 
• Low socioeconomic status(35) 
• Concerns about privacy and body discomfort 
during Pap examination are viewed as 
facilitators of self-sampling(23, 24) 
• Exclusive same-sex relationship is a facilitator 
for delaying screening debut to 25y(32) 











Table 2 (continued). Barriers and Facilitators of Healthcare Providers Acceptability of the HPV Test in Primary Screening for Cervical Cancer 
Factors corresponding to HCP’s practice environment 
Barriers Facilitators Contradictory evidence 
• Public outpatient setting (versus public hospital)(39) 
• Rural/military practice (versus suburban/urban)(17) 
• HPV testing guidelines not endorsed by HCP’s 
healthcare organization(36, 40) 
• HPV test not offered by their laboratory(36) 
• Caring for ≥ 25% black population(2) 
• Lower proportion (<75%) of privately insured 
patients(2, 36, 40) 
 
• Private and nonsolo (i.e., single specialty 
group) practice(2, 36) 
• Northeastern (versus Southern) US 
gynecologists(17) 
• Electronic medical system usage(30) 
 
• Timely access (on-site) to colposcopy(36) 
Healthcare system factors 
Barriers Facilitators Contradictory evidence 
• Opportunistic cervical cancer screening environment 
(e.g., postponing screening debut to 25y and 
extending screening intervals could facilitate women 
to lose contact with the medical system, higher HCP’s 
perceived risk of liability for extended screening 
intervals)(20, 32) 
• Screening guidelines in their jurisdiction (e.g., 
province) do not incorporate HPV testing(26)  
• Poor designed self-sampling information materials for 
women(23) 
• Use of personal communication of self-
sampling results to underscreened patients 
creates education opportunities and promotes 
women to return to the medical system(23) 
• Cost of screening for the patient: 
extended screening intervals decrease cost 
and could act as facilitator (Roland, 
2013), if the HPV test is not reimbursed 
HCP may not communicate the option(26, 
36, 40) 


















et al., 2011 
USA 
Cancer Screening Practices 
Among Physicians in the 
National Breast and Cervical 
Cancer Early Detection Program 
To describe the demographic 
and practice characteristics of 
participating and non-
participating physicians to the 
National Breast and Cervical 
Cancer Early Detection 
Program, as well as their 
beliefs, adoption of new 
screening technologies, and 
recommendations for breast 
and cervical cancer screening. 
886 physicians (FP, 







et al., 2016 
USA 
Change in Provider Beliefs 
Regarding Cervical Cancer 
Screening Intervals After an 
Educational Intervention 
The study objective was to 
assess 
changes in provider attitudes 
and beliefs to extending 
screening intervals among 
low-income women by using 
an educational intervention to 
promote recommended 
screening practices i.e., 
lengthening the screening 
interval to 3 years  
84 HCPs at baseline 
and 52 HCPs at 







Boone E. et 
al., 2016 
USA 
Discontent and Confusion: 
Primary Care Providers’ 
Opinions and Understanding 
of Current Cervical Cancer 
Screening Recommendations 
To elucidate causes of non-
adherence of primary care 
providers to primary screening 
for cervical cancer guidelines 
released in 2012 by ACOG, 
ACS, and USPSTF  
1268 HCPs 
(OB/GYN, FP, IM, 

















Cagliotti C. et 
al., 2017 
Italy 
Gynecologists and human 
papillomavirus DNA testing: 
exploring knowledge, attitudes, 
and practice in Italy 
To examine the knowledge, 
attitudes, and practice of 
OB/GYN related to the use of 
HPV DNA testing in primary 










Cost is a Barrier to Widespread 
Use of Liquid-Based Cytology 
for Cervical Cancer Screening in 
Korea 
This study aimed to document 
current cervical cancer 
screening practices of 
OB/GYN 






Cooper C.P. et 
al., 2015 
USA 
Perceived effectiveness of HPV 
test as a primary screening 
modality 
among US providers 
To explore HCPs perceptions 
of the effectiveness of the 
HPV test in population-based 
screening for cervical cancer  
 1040 HCPs in 2009 
(189 IM, 494 FP, 
141 NP and 216 
OB/GYN) and 1039 
HCPs in 2012 (205 
IM, 435 FP, 155 NP 






Cooper C.P.  
et al., 2017 
USA 
Primary HPV testing 
recommendations of US 
providers, 2015 
To examine physicians’ HPV 
testing recommendations 






Corbelli J. et 
al., 2014 
USA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
Differences Among Primary 
Care Physicians' Adherence to 
2009 ACOG Guidelines for 
Cervical Cancer Screening 
To assess the compliance of 
HCPs with 2009 
ACOG guidelines for cervical 
cancer screening 







Filade T. E. et 
al., 2017 
Nigeria 
Attitude to Human 
Papillomavirus 
Deoxyribonucleic Acid-Based 
Cervical Cancer Screening in 
Antenatal Care in Nigeria: A 
Qualitative Study 
To explore the 
attitude of HCPs and pregnant 
women toward the 
hypothetical introduction of 
HPV DNA testing into routine 
antenatal care  
82 pregnant women 
(focus groups) and 
13 HCPs (OB/GYN 



















Hoover K. et 
al., 2009 
USA 
Access of Black, Hispanic, and 
nonprivately insured women to 
liquid-based cytology, human 
papillomavirus DNA testing, 
and on-site colposcopy in the 
United States 
To determine if patients’ 
sociodemographics was 
associated with HCPs use of 
liquid-based cytology, HPV 











Irwin K. et al., 
2006 
USA 
Cervical cancer screening, 
abnormal cytology management, 
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